Oxford COVID-19 vaccine: Serum Institute to resume trial in India after DCGI's nod1 min read . Updated: 12 Sep 2020, 10:04 PM IST
- The recent chain of events are a clear example why we should not bias the process and should respect the process till the end, said Adar Poonawalla
After Astrazeneca resumed Oxford University coronavirus vaccine trial in the United Kingdom, Serum Institute of India on Saturday said that they will restart the trial in the country once the apex drug regulator allows. Commenting on the resumption of trial, Adar Poonawalla, the chief executive officer of Serum Institute of India said, "We should not jump to conclusions until the trials are fully concluded."
Select your Category